Immune reconstitution inflammatory syndrome (IRIS) is associated with clinical manifestations that can overlap with the patients with acquired immunodeficiency disease (AIDS)-related non-Hodgkin's lymphoma. We herein report a case of AIDS-related Burkitt lymphoma which was successfully treated with dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone (EPOCH). However, the patient developed a lymphoma-like clinical presentation shortly after the conclusion of chemotherapy. The patient's symptoms were identical to the initial symptoms characteristic of lymphoma; however, the laboratory data revealed no evidence of a relapse of Burkitt lymphoma. A bone marrow examination showed T-cell clonality, even though there were no signs of any progression of the lymphoma. The patient was diagnosed with IRIS, and the clinical manifestations rapidly improved following treatment.
Introduction
Burkitt lymphoma is the second most common form of lymphoma in patients with AIDS-related non-Hodgkin's lymphoma (ARL). Prior to the introduction of Highly Active Antiviral Therapy (HAART), the prognosis for patients with ARL was poor, with an overall survival rate of <1 year. Since the induction of HAART, the outcomes in patients with ARL have markedly improved due to the administration of high-intensive chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) or HCVAD.
Immune reconstitution inflammatory syndrome (IRIS) is defined as a paradoxic deterioration in the clinical status as a result of the recovery of the immune system during HAART. IRIS is associated with various clinical manifestations that overlap with the clinical manifestations which occur in patients with malignant lymphoma. The typical IRIS symptoms are associated with reactivation of opportunistic infections, such as Mycobacterium tuberculosis, M. avium complex, cytomegalovirus and pneumocystis pneumonia. Occasionally, there are some cases in which IRIS may occur in the brain without any opportunistic infection; these cases present as T cell-mediated encephalitis. We herein report a case in which a patient who was treated for ARL developed clinical manifestations that were consistent with a relapse of lymphoma shortly after the termination of the chemotherapy. The symptoms were attributed to IRIS.
Case Report
A 39-year-old homosexual man was diagnosed with human immunodeficiency virus (HIV) in 2003. He was followed without being medicated because his CD4 T-cell count was >350/μL; however, in November of 2011, the patient presented to the hospital with mandibular and left femur numbness. Head MRI showed no apparent invasions of lymphoma or any other central nerve system (CNS) disorders. A thoracoabdominal CT scan revealed left axillary lymphadenopathy which indicated lymphoma invasion (Fig. 1 ). The peripheral blood and bone marrow showed a marked invasion of lymphoma cells that were characteristi- In May 2012, he presented to the clinic with an acute onset of fatigue, high fevers and mandibular and left femur numbness, which were identical to the initial symptoms that he had at the onset of Burkitt lymphoma. The laboratory findings showed a marked elevation in his serum lactate dehydrogenase levels (LDH: 1,522 IU/L), with a decreased platelet count (14,000/μL). His CD4+ T-cell count was normal (962/μL), and his serum HIV-RNA level was reduced to <20 copy/mL. He was suspected to have an early relapse of Burkitt lymphoma, and was admitted to the hospital.
An examination of the bone marrow revealed an increase in the number of activated lymphocytes, but no lymphoma invasion was apparent ( Fig. 3) . A flow cytometry (FCM) analysis of the lymphocytosis gave the following results, which were compatible with a T-cell phenotype: CD2+, 99%; CD3+, 96%; CD4+, 22%; CD5+, 94%; CD7+, 82% and CD8+, 81%. The chromosome analysis showed the following: 46,XY,t(1;2)(q21;p13),der(5)t(1;5)(q12;q35), add(8) (q22),add(14)(q22) [5] /46,XY [15] . Since there were no apparent lymphoma cells, immunofluorescence staining of mib-1, c-myc, Epstein-Barr virus-encoded RNA in situ hybridization (EBER) and CD10 was not performed. Compared with the bone marrow findings at the initial presentation, these results were inconsistent with Burkitt lymphoma. Fluorescence in situ hybridization (FISH) for Immunoglobulin heavy locus, c-MYC translocation (IgH/C-MYC) had no fusion signals, but the T-cell receptor rearrangement was positive. Fluid attenuated inversion recovery (FLAIR) and enhanced axial T1-weighted (T1W1) MRI images of the head showed local enhancement in the trigeminal nerve, which was compatible with his neurological symptoms ( Fig. 4 ). An examination of the CSF revealed elevated mononuclear cells (590/μL). These cells also had a CD8 dominant T-cell phenotype and the cytologic diagnosis indicated a ClassIIIb morphology, but it was difficult to distinguish between the activated lymphocytes and the malignant cells. We also searched for various pathogens which could cause meningitis or systemic inflammation; however, the multiplex polymerase chain reaction (PCR) analysis for herpes (herpes simplex virus (HSV)-1, HSV-2, Epstein-Barr virus (EBV), human herpes virus (HHV)-6, varicella-zoster virus (VZV) and cytomegalovirus (CMV)) and other pathogens was negative (Table 1) .His serum EBV DNA assay revealed less than 20 copies; thus, we did not diagnose this patient with infectious meningitis. Between the laboratory data indicated above and the clinical symptoms of inflammation, along with the prompt elimination of his HIV-1 RNA levels, this patient was diagnosed with IRIS according to Shelburne's criteria (1) . At the time of admission, the patient was thought to have relapsed lymphoma, thus we treated him with a spinal injection of MTX/AraC/PSL and administered a single dose of prednisolone (1 mg/kg). The patient initially presented with a high fever, fatigue, neurologic symptoms and a marked elevation of LDH, but, shortly after treatment, the symptoms promptly improved with a normalization of the laboratory findings.
Discussion
The incidence of ARL is 10%-30% among AIDS patients. Indeed, ARL is the second most common neoplasm that is diagnosed in HIV-positive patients. The risk of developing these lymphomas is approximately 100-fold higher in HIVpositive patients than in the general population (2), and the vast majority of these lymphomas consist of aggressive Bcell malignancies (3) . The risk of developing ARL is reportedly dependent on the following factors: a low CD4 count (<100/μL), advanced-stage disease, >35 years of age, poor performance status, onset of AIDS, high serum LDH value, and refractory to HAART (3). HIV-positive patients with ARL tend to present with more advanced-stage disease, B symptoms, extranodal sites of disease and bone marrow and CNS involvement compared with HIV-negative, non-Hodgkin's lymphoma patients (3) .
The survival rates for AIDS-related diffuse large B-cell lymphoma have been significantly improved by the widespread use of HAART. The CR has improved to 74% with the use of dose-adjusted EPOCH, and, at 53 months median follow-up, the disease-free rate and the overall survival rate were 92% and 60% respectively (4) .
Burkitt lymphoma is the second most common non-Hodgkin's lymphoma in patients with ARL. When compared with diffuse large B-cell lymphoma, Burkitt lymphoma is associated with a significantly worse outcome even if treated with a CHOP-like regimen and the median overall survival duration is only 6 months (5, 6) . Recently, more intensive chemotherapy including CODOX-M/IVAC was shown to be well-tolerated with improved outcomes in patients with AIDS-related Burkitt lymphoma. The reported 2-year event-free survival rates ranged from 60% to 75%, which were similar to the rate for HIV-negative patients (7, 8) .
IRIS is defined as a paradoxic deterioration of opportunistic infections, autoimmune disease or neoplasms as a result of the recovery of the immune system after initiating HAART. The risk for IRIS is associated with an initial CD4 cell count <50/μL and a high HIV load (at least 10,000 copies/ml) (9) . Novak et al. reported that the median time between the start of the HAART and an IRIS event was 63 days (range: 7 to 170 days), with a morbidity rate of 10%. The immunopathogenesis of IRIS has been described as two phases of immune restoration (10) . Soon after the initiation of HAART, there is a rapid increase in the levels of CD4+ memory T-cells with an elimination in the HIV viral load. The recovery of the lost responses to the specific antigens occurs during this phase. The second phase of immune restoration occurs after several months of therapy, as the naïve T-cells gradually proliferate, and can last as long as 2 years. IRIS can occur during both phases of immune recovery, but the pathophysiology of CNS-IRIS is not yet well understood (10) .
The most common IRIS-defining diagnoses were candidiasis, cytomegalovirus infections, disseminated M. avium intracellulare, pneumocystis pneumonia, varicella zoster, Kaposi's sarcoma and non-Hodgkin's lymphoma (11) . The typical symptoms in patients with IRIS include fever, lymphadenopathy and pulmonary symptoms, all of which resemble the symptoms that occur in those patients with ARL. Shelburne et al. have proposed the following criteria for the diagnosis of IRIS: HIV positive, currently or recently received HAART, have achieved a reduction in the HIV-1 RNA levels from the baseline, an increase in CD4+ cells from the baseline, having clinical symptoms consistent with an inflammatory process, and demonstrating a clinical course that is not consistent with the expected course of the previously diagnosed or newly diagnosed opportunistic infections or drug toxicity (1). This case was consistent with these proposed criteria: thus, we diagnosed him as IRIS.
In this case, the neurologic symptoms may have been due to aseptic meningitis, although we could not detect the presence of any pathogens in his CSF. Enteroviral meningitis is a major cause of aseptic meningitis, but we did not investigate for this pathogen. Enterovirus may therefore not be a major cause of meningitis among the AIDS population.
IRIS may also occur in the brain without any opportunistic infection, which is termed as CNS-IRIS. Riedel et al. have established the diagnostic criteria for CNS-IRIS (Table 2) (10). In this case, we could detect T-cell infiltration in the CSF, and, together with the clinical symptoms and the laboratory examinations, his pathological condition meets the proposed criteria. MRI findings from the scans of the head also supported the diagnosis of CNS-IRIS. In addition, the systemic administration of corticosteroids promptly resolved the symptoms, which would not be the case for opportunistic infections or aseptic meningitis. Based on these findings, we concluded that this was a case of CNS-IRIS.
A previous report detailed the clinical courses of four patients with ARL who developed clinical manifestations similar to IRIS within a few months of receiving HAART. Among these four patients, three developed aggressive B cell lymphoma and one developed T-cell lymphoma. Each patient experienced a prompt progression of their disease and the outcomes were fatal in all patients (11) . The authors of this four-patient study noted that immune reconstitution as a result of HAART was a predisposing factor for the development of non-Hodgkin's lymphoma; thus non-Hodgkin's lymphoma should be suspected in any patient with lymphadenopathy that develops after an immune recovery due to HAART is important (11) . There are diagnostically challenging cases which exhibit lymphoma-like presentations during the immune reconstruction period that have resulted in IRIS with an exacerbation of opportunistic infections or tumor-like masses. Mortensen et al. reported a patient with deteriorating clinical manifestations and the development of a bulky mediastinum and peritoneal mass after the initiation of HAART. An ARL progression was highly suspected; however, no malignant cells were detected in the mediastinal mass, so the diagnosis of IRIS was made (12). Powles et al. reported three patients with IRIS that presented with symptoms of an ARL lymphoma relapse, but who were eventually diagnosed with exacerbations of mycobacterial infections (13) .
For the patient presented herein, the neurologic symptoms were identical to the initial manifestations of Burkitt lymphoma. In addition, the laboratory findings showed a marked elevation of the serum LDH levels, a low platelet count and lymphocyte invasion of the CSF, all of which were highly suggestive of recurrent ARL. Even though there was no evidence of Burkitt lymphoma relapse, we could not rule out the occurrence of a T-cell lymphoma. Taken together, if we consider that the lymphoma-like symptoms occurred at the time of the immunologic recovery from chemotherapy with a reasonable anti-HIV effect by HAART, then these systemic inflammatory episodes were likely due to IRIS rather than to lymphoma relapse. Nevertheless, there is still a possibility that the patient had an occurrence of Tcell lymphoma at the time of IRIS, even though was no evidence of any progression of T-cell lymphoma at 6 months after the diagnosis of IRIS.
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